Celli BR. Standards for the optimal management of COPD: A summary. Chest 1998; 113: S283-287.
Wijkstra PJ, Jones PW. Quality of life in patients with chronic obstructive pulmonary disease. Eur Respir Mon 1998; 7: 235-246.
Anthonisen NR, Connett JE, Kiley JP, et al. The Lung Health Study Research Group. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA 1994; 272: 1497-1505.
Pauwels RA, Löfdahl C-G, Laitinen LA, et al. The European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-1953.
Vestbo J, Sø rensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999; 353: 1819-1823.
Mahler DA, Tomlinson D, Olmstead EM, et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995; 151: 61-65.
van Schayck CP, Rutten-van Mölken MPMH, van Doorslaer EKA, et al. Two-year bronchodilator treatment in patients with mild airflow obstruction: Contradictory effects on lung function and quality of life. Chest 1992; 102: 1384-1391.
van Schayck CP, Dompeling E, Rutten MPMH, et al. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 1995; 107: 1199-1205.
Spencer S, Calverley PMA, Burge PS, Jones PW on behalf of the ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122-128.
Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
Ware JE, Sherbourne CD. The MOS 36-item short-from health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
American Thoracic Society-European Respiratory Society Longitudinal Data Analysis Workshop. Am J Respir Crit Care Med 1996; 154: S207-284.
Strachan D, Sherrill D. Statistical methods. Eur Respir J 1998; 12: S23-27.
Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-778.
Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-120.
Medical Section of the American Lung Association. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1994; 152: 1107-1136.
Japan Society of Chest Diseases. The predicted values of pulmonary function testing in Japanese. Jpn J Thoracic Dis 1993; 31: Appendix [in Japanese].
Hajiro T, Nishimura K, Tsukino M, et al. Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 785-790.
Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, North Carolina: SAS Institute, Inc., 1996.
Burge PS, Calverley PMA, Jones PW, et al. on behalf of the ISOLDE study investigators. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000; 320: 1297-1303.
Guyatt GH, King DR, Feeny DH, et al. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol 1999; 52: 187-192.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.
Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med 1991; 85(Suppl B): 25-31.
Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398-404.
Singh SJ, Sodergren SC, Hyland ME, et al. A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD. Respir Med 2001; 95: 71-77.
Wedzicha JA, Bestall JC, Garrod R, et al. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 1998; 12: 363-369.
Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880-887.
Curran D, Bacchi M, Hsu Schmitz SF, et al. Identifying the types of missingness in quality of life data from clinical trials. Stat Med 1998; 17: 739-756.
Park T. A comparison of the generalized estimating equation approach with the maximum likelihood approach for repeated measurements. Stat Med 1993; 12: 1723-1732.
Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127: 1072-1079.
van Manen JG, Bindels PJ, Dekker EW, et al. Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respir Med 2001; 95: 496-504.
Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
Janssens JP, Rochat T, Frey JG, et al. Health-related quality of life in patients under long-term oxygen therapy: A home-based descriptive study. Respir Med 1997; 91: 592-602.